• Oramed Pharmaceuticals CFO Avraham Gabay sold 73,360 common shares on July 1.
• Shares were sold at a weighted average price of $4.51.
• Gabay’s direct holding fell to 671,785 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-075069), on July 02, 2026, and is solely responsible for the information contained therein.